The Bispecific Inflection Point: A Strategic Analysis of a Modality’s Industrialization
The concept of an antibody engaging two targets simultaneously is not new; it has been a subject of scientific inquiry for decades. What is new, and what represents a structural transformation in the biopharmaceutical industry, is the industrial-scale convergence of clinical validation, manufacturing capability, and strategic capital that has elevated bispecific antibodies (BsAbs) from […]
Reimbursement: The True Bottleneck for Radioligand Therapies in Europe?
Reimbursement: The True Bottleneck for Radioligand Therapies in Europe…? Radioligand therapies (RLTs) represent a groundbreaking advancement in oncology, offering highly targeted treatment for various cancers, including prostate and neuroendocrine tumors. These innovative therapies hold immense promise, delivering precise radiation directly to cancer cells while minimizing harm to healthy tissue. A core innovation within RLT lies […]